IGC Pharma, Inc.
IGC
$0.29
$0.000.32%
AMEX
| 06/30/2026 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -16.40% | -0.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.40% | -0.61% | |||
| Cost of Revenue | -17.18% | -1.14% | |||
| Gross Profit | -12.73% | 0.00% | |||
| SG&A Expenses | 16.20% | 94.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.87% | 24.44% | |||
| Operating Income | -13.26% | -30.10% | |||
| Income Before Tax | -22.23% | -33.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.23% | -33.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.23% | -33.58% | |||
| EBIT | -13.26% | -30.10% | |||
| EBITDA | -13.67% | -34.63% | |||
| EPS Basic | -19.59% | -28.67% | |||
| Normalized Basic EPS | -19.61% | -20.00% | |||
| EPS Diluted | -19.59% | -28.67% | |||
| Normalized Diluted EPS | -19.61% | -20.00% | |||
| Average Basic Shares Outstanding | 2.21% | 4.32% | |||
| Average Diluted Shares Outstanding | 2.21% | 4.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||